Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dietary Proteins | 16 | 1998 | 51 | 1.040 |
Why?
|
| Albuminuria | 16 | 2003 | 171 | 0.600 |
Why?
|
| Enalapril | 13 | 1998 | 86 | 0.590 |
Why?
|
| Glomerulonephritis | 10 | 2003 | 77 | 0.570 |
Why?
|
| Nephrotic Syndrome | 9 | 1999 | 61 | 0.490 |
Why?
|
| Proteinuria | 8 | 1995 | 136 | 0.480 |
Why?
|
| Albumins | 7 | 1996 | 72 | 0.420 |
Why?
|
| Kidney Failure, Chronic | 3 | 2006 | 365 | 0.410 |
Why?
|
| Angiotensin II | 5 | 2004 | 220 | 0.350 |
Why?
|
| Kidney | 10 | 2011 | 945 | 0.340 |
Why?
|
| Urban Population | 2 | 2006 | 255 | 0.300 |
Why?
|
| Geographic Information Systems | 1 | 2006 | 34 | 0.260 |
Why?
|
| Urban Health | 1 | 2006 | 49 | 0.260 |
Why?
|
| Rural Health | 1 | 2006 | 66 | 0.260 |
Why?
|
| Kinins | 3 | 1995 | 109 | 0.250 |
Why?
|
| Hypertension | 3 | 2014 | 1535 | 0.240 |
Why?
|
| Renal Dialysis | 2 | 2003 | 174 | 0.230 |
Why?
|
| Rural Population | 1 | 2006 | 398 | 0.220 |
Why?
|
| Glomerular Filtration Rate | 7 | 2011 | 274 | 0.200 |
Why?
|
| Rats | 20 | 2004 | 5300 | 0.200 |
Why?
|
| Hyperlipidemias | 3 | 1993 | 90 | 0.200 |
Why?
|
| Serum Albumin | 6 | 1995 | 104 | 0.190 |
Why?
|
| Health Care Costs | 1 | 2003 | 346 | 0.180 |
Why?
|
| Kidney Diseases | 4 | 2005 | 307 | 0.170 |
Why?
|
| Nephritis | 3 | 1990 | 37 | 0.170 |
Why?
|
| Rats, Inbred Strains | 10 | 1991 | 532 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 1998 | 202 | 0.160 |
Why?
|
| Male | 27 | 2014 | 37321 | 0.140 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 1995 | 38 | 0.140 |
Why?
|
| Kidney Tubules, Proximal | 1 | 1996 | 81 | 0.130 |
Why?
|
| Animals | 24 | 2011 | 20881 | 0.130 |
Why?
|
| Kallikreins | 2 | 1993 | 323 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 1993 | 562 | 0.120 |
Why?
|
| Renin | 2 | 1993 | 96 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2004 | 2083 | 0.110 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1993 | 8 | 0.110 |
Why?
|
| Nutrition Surveys | 1 | 2014 | 208 | 0.110 |
Why?
|
| Eicosanoids | 1 | 1993 | 16 | 0.110 |
Why?
|
| Kidney Glomerulus | 4 | 1999 | 155 | 0.100 |
Why?
|
| Osteomalacia | 1 | 1992 | 8 | 0.100 |
Why?
|
| Rickets | 1 | 1992 | 20 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1993 | 282 | 0.100 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 1991 | 2 | 0.100 |
Why?
|
| Thromboxane A2 | 1 | 2011 | 88 | 0.090 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2011 | 46 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 407 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2011 | 141 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2011 | 190 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 1993 | 1664 | 0.080 |
Why?
|
| Lupus Nephritis | 1 | 2011 | 193 | 0.080 |
Why?
|
| Muramidase | 1 | 1988 | 38 | 0.080 |
Why?
|
| South Carolina | 2 | 2006 | 2752 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2004 | 317 | 0.070 |
Why?
|
| Prevalence | 2 | 2014 | 1619 | 0.070 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1987 | 84 | 0.070 |
Why?
|
| Aldosterone | 2 | 1999 | 51 | 0.070 |
Why?
|
| Geography | 1 | 2006 | 80 | 0.070 |
Why?
|
| Southeastern United States | 1 | 2006 | 281 | 0.070 |
Why?
|
| Female | 9 | 2014 | 38074 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 1998 | 155 | 0.060 |
Why?
|
| Middle Aged | 8 | 2014 | 21147 | 0.060 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 83 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 320 | 0.060 |
Why?
|
| Humans | 14 | 2014 | 68618 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2005 | 281 | 0.060 |
Why?
|
| Body Composition | 1 | 2005 | 119 | 0.060 |
Why?
|
| Homeostasis | 1 | 1986 | 291 | 0.060 |
Why?
|
| Aged | 6 | 2006 | 14862 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2006 | 581 | 0.060 |
Why?
|
| Receptor, Bradykinin B2 | 1 | 2004 | 75 | 0.060 |
Why?
|
| Cost Allocation | 1 | 2003 | 4 | 0.060 |
Why?
|
| Fees and Charges | 1 | 2003 | 11 | 0.060 |
Why?
|
| Diagnosis-Related Groups | 1 | 2003 | 28 | 0.060 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2003 | 5 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 107 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2003 | 69 | 0.050 |
Why?
|
| Drug Costs | 1 | 2003 | 87 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2003 | 117 | 0.050 |
Why?
|
| Registries | 1 | 2006 | 733 | 0.050 |
Why?
|
| Antihypertensive Agents | 2 | 2014 | 498 | 0.050 |
Why?
|
| Adult | 6 | 2006 | 21403 | 0.050 |
Why?
|
| Incidence | 1 | 2006 | 1603 | 0.050 |
Why?
|
| Risk Factors | 2 | 2014 | 5731 | 0.050 |
Why?
|
| Losartan | 2 | 1998 | 45 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2003 | 434 | 0.050 |
Why?
|
| Receptors, Angiotensin | 2 | 1998 | 59 | 0.040 |
Why?
|
| Thromboxane B2 | 2 | 2011 | 108 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2006 | 2455 | 0.040 |
Why?
|
| Infant | 1 | 2006 | 2891 | 0.040 |
Why?
|
| Comorbidity | 1 | 2003 | 1426 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2006 | 3187 | 0.040 |
Why?
|
| Organ Size | 3 | 1999 | 242 | 0.040 |
Why?
|
| Mice, Inbred MRL lpr | 2 | 2011 | 118 | 0.040 |
Why?
|
| Base Sequence | 2 | 2003 | 1015 | 0.040 |
Why?
|
| Hospitalization | 1 | 2003 | 978 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2003 | 711 | 0.040 |
Why?
|
| Reference Values | 2 | 1999 | 579 | 0.040 |
Why?
|
| Absorption | 1 | 1996 | 49 | 0.030 |
Why?
|
| Basement Membrane | 1 | 1996 | 48 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 134 | 0.030 |
Why?
|
| Microinjections | 1 | 1996 | 130 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 1996 | 195 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2003 | 3705 | 0.030 |
Why?
|
| Hypertension, Renovascular | 1 | 1995 | 47 | 0.030 |
Why?
|
| Child | 1 | 2006 | 6405 | 0.030 |
Why?
|
| Time Factors | 2 | 1995 | 4655 | 0.030 |
Why?
|
| Bradykinin | 1 | 1995 | 157 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 1995 | 184 | 0.030 |
Why?
|
| Tetrazoles | 1 | 1995 | 160 | 0.030 |
Why?
|
| Imidazoles | 1 | 1995 | 175 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 4848 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 35 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1993 | 189 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2014 | 201 | 0.030 |
Why?
|
| Adolescent | 1 | 2006 | 8912 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 1993 | 94 | 0.030 |
Why?
|
| Lipoproteins | 1 | 1993 | 161 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1992 | 166 | 0.020 |
Why?
|
| Kinetics | 1 | 1993 | 1047 | 0.020 |
Why?
|
| Blood Pressure | 2 | 1995 | 1451 | 0.020 |
Why?
|
| Body Weight | 2 | 1995 | 554 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1046 | 0.020 |
Why?
|
| Bone and Bones | 1 | 1992 | 145 | 0.020 |
Why?
|
| Glucagon | 1 | 1991 | 22 | 0.020 |
Why?
|
| Nitrites | 1 | 2011 | 53 | 0.020 |
Why?
|
| Nitrates | 1 | 2011 | 61 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 1447 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1420 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1993 | 240 | 0.020 |
Why?
|
| Radiography | 1 | 1992 | 572 | 0.020 |
Why?
|
| Amino Acids | 1 | 1991 | 131 | 0.020 |
Why?
|
| Growth | 1 | 1989 | 17 | 0.020 |
Why?
|
| Ornithine Decarboxylase | 1 | 1989 | 17 | 0.020 |
Why?
|
| Arginase | 1 | 1989 | 15 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 532 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1992 | 951 | 0.020 |
Why?
|
| Dinoprost | 1 | 1989 | 27 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 1992 | 292 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2011 | 382 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 694 | 0.020 |
Why?
|
| Dinoprostone | 1 | 1989 | 110 | 0.020 |
Why?
|
| United States | 2 | 2014 | 7367 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Triglycerides | 1 | 1987 | 184 | 0.020 |
Why?
|
| Rats, Wistar | 2 | 1999 | 371 | 0.020 |
Why?
|
| Cholesterol | 1 | 1987 | 331 | 0.020 |
Why?
|
| Mice | 2 | 2011 | 8474 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 1987 | 249 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 245 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 1999 | 1040 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2005 | 91 | 0.020 |
Why?
|
| Liver | 1 | 1989 | 1118 | 0.010 |
Why?
|
| Extracellular Fluid | 1 | 2004 | 29 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2005 | 307 | 0.010 |
Why?
|
| Joints | 1 | 2003 | 30 | 0.010 |
Why?
|
| Joint Diseases | 1 | 2003 | 37 | 0.010 |
Why?
|
| Aorta | 1 | 2004 | 316 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 241 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 867 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 1465 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2003 | 175 | 0.010 |
Why?
|
| Gene Expression | 1 | 2004 | 770 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1753 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 329 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 481 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1851 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 2358 | 0.010 |
Why?
|
| Rats, Inbred WF | 1 | 1999 | 14 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 597 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1999 | 114 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1999 | 103 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2673 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 306 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 1999 | 152 | 0.010 |
Why?
|
| Lung | 1 | 2003 | 849 | 0.010 |
Why?
|
| Biomarkers | 1 | 2003 | 1593 | 0.010 |
Why?
|
| Alcian Blue | 1 | 1996 | 5 | 0.010 |
Why?
|
| Anions | 1 | 1996 | 12 | 0.010 |
Why?
|
| Laminin | 1 | 1996 | 62 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1996 | 66 | 0.010 |
Why?
|
| Fibronectins | 1 | 1996 | 130 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2004 | 2689 | 0.010 |
Why?
|
| Random Allocation | 1 | 1995 | 442 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1996 | 370 | 0.010 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1993 | 41 | 0.010 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 1993 | 52 | 0.010 |
Why?
|
| Leucine | 1 | 1993 | 41 | 0.010 |
Why?
|
| Collagen | 1 | 1996 | 636 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1993 | 260 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1993 | 289 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1993 | 150 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1995 | 705 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1999 | 2550 | 0.010 |
Why?
|
| Chylomicrons | 1 | 1990 | 6 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1993 | 682 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1990 | 48 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 1 | 1990 | 32 | 0.010 |
Why?
|
| Glycopeptides | 1 | 1990 | 15 | 0.010 |
Why?
|
| Neprilysin | 1 | 1990 | 55 | 0.010 |
Why?
|
| Aprotinin | 1 | 1990 | 55 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1990 | 186 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1989 | 164 | 0.010 |
Why?
|
| Renin-Angiotensin System | 1 | 1989 | 79 | 0.010 |
Why?
|